TW201622716A - 治療增劇非酒精性脂肪肝炎之方法 - Google Patents

治療增劇非酒精性脂肪肝炎之方法 Download PDF

Info

Publication number
TW201622716A
TW201622716A TW104114464A TW104114464A TW201622716A TW 201622716 A TW201622716 A TW 201622716A TW 104114464 A TW104114464 A TW 104114464A TW 104114464 A TW104114464 A TW 104114464A TW 201622716 A TW201622716 A TW 201622716A
Authority
TW
Taiwan
Prior art keywords
compound
formula
liver
patient
group
Prior art date
Application number
TW104114464A
Other languages
English (en)
Chinese (zh)
Inventor
松田和子
岩城裕一
Original Assignee
梅迪西諾瓦股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 梅迪西諾瓦股份有限公司 filed Critical 梅迪西諾瓦股份有限公司
Publication of TW201622716A publication Critical patent/TW201622716A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/121Ketones acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Alcoholic Beverages (AREA)
  • Steroid Compounds (AREA)
TW104114464A 2014-05-08 2015-05-06 治療增劇非酒精性脂肪肝炎之方法 TW201622716A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990606P 2014-05-08 2014-05-08
US201462042072P 2014-08-26 2014-08-26
US14/490,618 US9346754B2 (en) 2014-05-08 2014-09-18 Method of treating advanced non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
TW201622716A true TW201622716A (zh) 2016-07-01

Family

ID=54367221

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104114464A TW201622716A (zh) 2014-05-08 2015-05-06 治療增劇非酒精性脂肪肝炎之方法

Country Status (10)

Country Link
US (1) US9346754B2 (enExample)
EP (1) EP3139911B1 (enExample)
JP (1) JP6672173B2 (enExample)
KR (1) KR102386018B1 (enExample)
CN (1) CN106456576A (enExample)
BR (1) BR112016025369A2 (enExample)
CA (2) CA2946597C (enExample)
ES (1) ES2964286T3 (enExample)
TW (1) TW201622716A (enExample)
WO (1) WO2015171755A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457306B2 (en) * 2014-10-07 2016-10-04 Life Technologies Corporation Regulated vacuum off-gassing of gas filter for fluid processing system and related methods
EP4346783A1 (en) * 2021-05-28 2024-04-10 MediciNova, Inc. Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5290812A (en) 1991-01-18 1994-03-01 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
US7060854B2 (en) 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
MXPA06012564A (es) * 2004-04-27 2007-01-31 Medicinova Inc Derivados de acido fenoxialquilcarboxilico en el tratamiento de enfermedades inflamatorias.
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
JP2013056834A (ja) * 2011-09-07 2013-03-28 Okayama Univ 線維化疾患治療剤
US8835499B2 (en) * 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis

Also Published As

Publication number Publication date
BR112016025369A2 (pt) 2017-08-15
KR102386018B1 (ko) 2022-04-14
CA3205812A1 (en) 2015-11-12
KR20170003581A (ko) 2017-01-09
CA2946597C (en) 2023-09-12
WO2015171755A2 (en) 2015-11-12
ES2964286T3 (es) 2024-04-05
JP2017518967A (ja) 2017-07-13
EP3139911A4 (en) 2017-12-20
EP3139911A2 (en) 2017-03-15
CN106456576A (zh) 2017-02-22
EP3139911B1 (en) 2023-10-25
US9346754B2 (en) 2016-05-24
CA2946597A1 (en) 2015-11-12
US20150322004A1 (en) 2015-11-12
JP6672173B2 (ja) 2020-03-25

Similar Documents

Publication Publication Date Title
JP2019218379A (ja) 肝障害の治療方法
JP6608404B2 (ja) 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
TW201622716A (zh) 治療增劇非酒精性脂肪肝炎之方法
WO2017155053A1 (ja) 非アルコール性脂肪性肝疾患/非アルコール性脂肪性肝炎の治療剤
Qin et al. Small molecule-driven LKB1 deacetylation is responsible for the inhibition of hepatic lipid response in NAFLD
WO2021202546A1 (en) Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death
CN119700764B (zh) 恩波吡维铵在制备抗基孔肯亚病毒感染药物中的应用
US20150320705A1 (en) Method of inhibiting or treating amyotrophic lateral sclerosis with phenoxyalkylcarboxylic acids
CN110755621B (zh) 一种包含Senp表达调节试剂的组合物及其在制备抗肝纤维化药物中的应用
US12239620B2 (en) Methods to decrease triglyceride synthesis in the liver
US20250041255A1 (en) Compositions and methods for treating autoimmune skin diseases
US20230355596A1 (en) Compositions and methods of using nmdar inhibitors and kinase inhibitors to treat liver cancer
CN119632971A (zh) 一种达泮舒腈的应用及药物